Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Leleu

Showing results (51-60 of 372) with videos related to

Pageof 38
Sort By:
Leukemia & Lymphoma|December 29, 2004
Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myelomaStephane Depil, Xavier Leleu, Jean-Baptiste Micol, et al.
Blood|August 15, 2002
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyPhilippe Moreau, Thierry Facon, Xavier Leleu, et al.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2022
Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohortEmilie Chalayer, Alexis Talbot, Laurent Frenzel, et al.
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs in multiple myelomaIrene M Ghobrial, Xavier Leleu, Evdoxia Hatjiharissi, et al.
European Journal of Haematology|May 18, 2023
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare databaseXavier Leleu, Boris Gorsh, Antoine Bessou, et al.
Leukemia & Lymphoma|September 18, 2008
Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplantAna B Oton, Hong Wang, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 6, 2018
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple MyelomaXavier Leleu, Thomas G Martin, Hermann Einsele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Targeting the phosphatidylinositol 3-kinase pathway in multiple myelomaHashem Younes, Xavier Leleu, Evdoxia Hatjiharissi, et al.
The Journal of Rheumatology|November 3, 2012
Osteolytic lesion with thick sclerotic walls and demyelinating polyneuropathyAlexandra Forestier, Guillaume Lefebvre, Xavier Leroy, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial SubanalysisSalomon Manier, Meletios Dimopoulos, Cyrille Hulin, et al.
Pageof 38

Showing results (51-60 of 372) with videos related to

Sort By:
Pageof 38
Leukemia & Lymphoma|December 29, 2004
Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myelomaStephane Depil, Xavier Leleu, Jean-Baptiste Micol, et al.
Blood|August 15, 2002
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyPhilippe Moreau, Thierry Facon, Xavier Leleu, et al.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2022
Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohortEmilie Chalayer, Alexis Talbot, Laurent Frenzel, et al.
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs in multiple myelomaIrene M Ghobrial, Xavier Leleu, Evdoxia Hatjiharissi, et al.
European Journal of Haematology|May 18, 2023
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare databaseXavier Leleu, Boris Gorsh, Antoine Bessou, et al.
Leukemia & Lymphoma|September 18, 2008
Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplantAna B Oton, Hong Wang, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 6, 2018
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple MyelomaXavier Leleu, Thomas G Martin, Hermann Einsele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Targeting the phosphatidylinositol 3-kinase pathway in multiple myelomaHashem Younes, Xavier Leleu, Evdoxia Hatjiharissi, et al.
The Journal of Rheumatology|November 3, 2012
Osteolytic lesion with thick sclerotic walls and demyelinating polyneuropathyAlexandra Forestier, Guillaume Lefebvre, Xavier Leroy, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial SubanalysisSalomon Manier, Meletios Dimopoulos, Cyrille Hulin, et al.
Pageof 38